Clinical Research Division, Fred Hutch
Dr. Petros Grivas is an oncologist with expertise in treating genitourinary cancers such as bladder cancer, prostate cancer and testicular cancer. His clinical research helped lead to FDA approval of new drugs to treat the most common type of bladder cancer. Dr. Grivas currently leads clinical trials that investigate the use of checkpoint inhibitors. These immunotherapy drugs release the brakes on a patient’s immune system and help it mount a better response to cancer.
Genitourinary Cancers Program, University of Washington Medicine
Associate Professor, Department of Medicine
Division of Oncology, University of Washington School of Medicine
Fellowship:Hematology/Oncology, University of Michigan
Residency: Drexel University College of Medicine/Hahnemann University Hospital, Philadelphia, PA
Ph.D.: Medical Oncology, University of Patras School of Medicine, Greece
M.D.: University of Patras School of Medicine, Greece
Study Number: RG1003487
Study Number: RG1005409
Study Number: RG1003350
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.